• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HCV 核心蛋白作为 DNA 免疫原在小鼠体内的免疫原性可通过诱导氧化应激及其应答的能力来调节。

The Immunogenicity in Mice of HCV Core Delivered as DNA Is Modulated by Its Capacity to Induce Oxidative Stress and Oxidative Stress Response.

机构信息

Department of Pathology, Riga Stradins University, LV-1007 Riga, Latvia.

Latvian Biomedical Research and Study Centre, LV-1067 Riga, Latvia.

出版信息

Cells. 2019 Feb 28;8(3):208. doi: 10.3390/cells8030208.

DOI:10.3390/cells8030208
PMID:30823485
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6468923/
Abstract

HCV core is an attractive HCV vaccine target, however, clinical or preclinical trials of core-based vaccines showed little success. We aimed to delineate what restricts its immunogenicity and improve immunogenic performance in mice. We designed plasmids encoding full-length HCV 1b core and its variants truncated after amino acids (aa) 60, 98, 152, 173, or up to aa 36 using virus-derived or synthetic polynucleotides (core191/60/98/152/173/36_191v or core152s DNA, respectively). We assessed their level of expression, route of degradation, ability to trigger the production of reactive oxygen species/ROS, and to activate the components of the Nrf2/ARE antioxidant defense pathway heme oxygenase 1/HO-1 and NAD(P)H: quinone oxidoreductase/Nqo-1. All core variants with the intact N-terminus induced production of ROS, and up-regulated expression of HO-1 and Nqo-1. The capacity of core variants to induce ROS and up-regulate HO-1 and Nqo-1 expression predetermined their immunogenicity in DNA-immunized BALB/c and C57BL/6 mice. The most immunogenic was core 152s, expressed at a modest level and inducing moderate oxidative stress and oxidative stress response. Thus, immunogenicity of HCV core is shaped by its ability to induce ROS and oxidative stress response. These considerations are important in understanding the mechanisms of viral suppression of cellular immune response and in HCV vaccine design.

摘要

丙型肝炎病毒核心是一种有吸引力的丙型肝炎病毒疫苗靶点,然而,基于核心的临床或临床前疫苗试验显示效果甚微。我们旨在阐明限制其免疫原性的因素,并提高其在小鼠中的免疫原性。我们设计了编码全长丙型肝炎病毒 1b 核心及其在氨基酸(aa)60、98、152、173 或最多至 aa 36 后截断的变体的质粒,使用病毒衍生或合成多核苷酸(core191/60/98/152/173/36_191v 或 core152s DNA)。我们评估了它们的表达水平、降解途径、触发活性氧(ROS)产生的能力、以及激活 Nrf2/ARE 抗氧化防御途径血红素加氧酶 1(HO-1)和 NAD(P)H:醌氧化还原酶/Nqo-1 的成分的能力。所有具有完整 N 末端的核心变体均可诱导 ROS 的产生,并上调 HO-1 和 Nqo-1 的表达。核心变体诱导 ROS 产生和上调 HO-1 和 Nqo-1 表达的能力决定了其在 DNA 免疫的 BALB/c 和 C57BL/6 小鼠中的免疫原性。最具免疫原性的是核心 152s,其表达水平适度,可诱导适度的氧化应激和氧化应激反应。因此,丙型肝炎病毒核心的免疫原性由其诱导 ROS 和氧化应激反应的能力决定。这些考虑因素对于理解病毒抑制细胞免疫反应的机制以及丙型肝炎病毒疫苗设计非常重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcb7/6468923/45d99f1eed13/cells-08-00208-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcb7/6468923/762a1e93cf3f/cells-08-00208-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcb7/6468923/bcbf6f6378e3/cells-08-00208-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcb7/6468923/6c2a8b0b767c/cells-08-00208-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcb7/6468923/3309fe4bdcb2/cells-08-00208-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcb7/6468923/abca87906002/cells-08-00208-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcb7/6468923/1db3ba6048bb/cells-08-00208-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcb7/6468923/45d99f1eed13/cells-08-00208-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcb7/6468923/762a1e93cf3f/cells-08-00208-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcb7/6468923/bcbf6f6378e3/cells-08-00208-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcb7/6468923/6c2a8b0b767c/cells-08-00208-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcb7/6468923/3309fe4bdcb2/cells-08-00208-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcb7/6468923/abca87906002/cells-08-00208-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcb7/6468923/1db3ba6048bb/cells-08-00208-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dcb7/6468923/45d99f1eed13/cells-08-00208-g007.jpg

相似文献

1
The Immunogenicity in Mice of HCV Core Delivered as DNA Is Modulated by Its Capacity to Induce Oxidative Stress and Oxidative Stress Response.HCV 核心蛋白作为 DNA 免疫原在小鼠体内的免疫原性可通过诱导氧化应激及其应答的能力来调节。
Cells. 2019 Feb 28;8(3):208. doi: 10.3390/cells8030208.
2
Oxidative stress induced by HIV-1 reverse transcriptase modulates the enzyme's performance in gene immunization.HIV-1 逆转录酶诱导的氧化应激调节了该酶在基因免疫中的作用。
Hum Vaccin Immunother. 2013 Oct;9(10):2111-9. doi: 10.4161/hv.25813. Epub 2013 Jul 23.
3
Hepatitis C virus (HCV) core protein enhances the immunogenicity of a co-delivered DNA vaccine encoding HCV structural antigens in mice.丙型肝炎病毒(HCV)核心蛋白增强了共递送的编码HCV结构抗原的DNA疫苗在小鼠体内的免疫原性。
Biotechnol Appl Biochem. 2006 Apr;44(Pt 1):9-17. doi: 10.1042/BA20050202.
4
[Enhancement of cellular immune response to DNA vaccine encoding hepatitis C virus core and envelope 2 fusion antigen by murine Fms-like tyrosine kinase 3 ligand].[小鼠Fms样酪氨酸激酶3配体增强对编码丙型肝炎病毒核心和包膜2融合抗原的DNA疫苗的细胞免疫应答]
Sheng Wu Gong Cheng Xue Bao. 2003 Mar;19(2):158-62.
5
Genetic immunization of wild-type and hepatitis C virus transgenic mice reveals a hierarchy of cellular immune response and tolerance induction against hepatitis C virus structural proteins.野生型和丙型肝炎病毒转基因小鼠的基因免疫揭示了针对丙型肝炎病毒结构蛋白的细胞免疫反应和耐受诱导的层次结构。
J Virol. 2001 Dec;75(24):12121-7. doi: 10.1128/JVI.75.24.12121-12127.2001.
6
Co-delivery of GM-CSF gene enhances the immune responses of hepatitis C viral core protein-expressing DNA vaccine: role of dendritic cells.GM-CSF基因共递送增强表达丙型肝炎病毒核心蛋白的DNA疫苗的免疫反应:树突状细胞的作用
J Med Virol. 2002 Mar;66(3):320-8. doi: 10.1002/jmv.2148.
7
Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice.口服免疫减毒沙门氏菌携带 co-expression 质粒,编码丙型肝炎病毒的核心和 E2 蛋白,能够在小鼠中诱导细胞免疫应答和中和抗体。
Vaccine. 2011 May 9;29(20):3714-23. doi: 10.1016/j.vaccine.2011.02.083. Epub 2011 Mar 9.
8
Hepatitis B virus precore protein augments genetic immunizations of the truncated hepatitis C virus core in BALB/c mice.乙肝病毒前核心蛋白增强BALB/c小鼠中截短型丙肝病毒核心蛋白的基因免疫效果。
Hepatology. 2008 Jan;47(1):25-34. doi: 10.1002/hep.21992.
9
HCV core protein-expressing DNA vaccine induces a strong class I-binding peptide DTH response in mice.表达丙肝病毒核心蛋白的DNA疫苗在小鼠中诱导出强烈的I类结合肽迟发型超敏反应。
Biochem Biophys Res Commun. 2004 Feb 13;314(3):781-6. doi: 10.1016/j.bbrc.2003.12.168.
10
The structural HCV genes delivered by MPG cell penetrating peptide are directed to enhance immune responses in mice model.由MPG细胞穿透肽递送的丙型肝炎病毒(HCV)结构基因旨在增强小鼠模型中的免疫反应。
Drug Deliv. 2016 Oct;23(8):2852-2859. doi: 10.3109/10717544.2015.1108375. Epub 2015 Nov 11.

引用本文的文献

1
Cellular Immune Response Induced by DNA Immunization of Mice with Drug Resistant Integrases of HIV-1 Clade A Offers Partial Protection against Growth and Metastatic Activity of Integrase-Expressing Adenocarcinoma Cells.用HIV-1 A亚型耐药整合酶对小鼠进行DNA免疫诱导的细胞免疫反应,对表达整合酶的腺癌细胞的生长和转移活性提供部分保护。
Microorganisms. 2021 Jun 4;9(6):1219. doi: 10.3390/microorganisms9061219.
2
Reciprocal Inhibition of Immunogenic Performance in Mice of Two Potent DNA Immunogens Targeting HCV-Related Liver Cancer.两种靶向丙型肝炎病毒相关肝癌的强效DNA免疫原在小鼠体内免疫原性表现的相互抑制作用
Microorganisms. 2021 May 17;9(5):1073. doi: 10.3390/microorganisms9051073.
3

本文引用的文献

1
Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.在纳入监测项目的肝硬化患者中,直接抗病毒治疗 HCV 后肝细胞癌的发生率。
Gastroenterology. 2018 Nov;155(5):1436-1450.e6. doi: 10.1053/j.gastro.2018.07.015. Epub 2018 Jul 19.
2
DNA immunization site determines the level of gene expression and the magnitude, but not the type of the induced immune response.DNA 免疫接种部位决定基因表达水平和幅度,但不决定诱导免疫应答的类型。
PLoS One. 2018 Jun 4;13(6):e0197902. doi: 10.1371/journal.pone.0197902. eCollection 2018.
3
Codon optimization and improved delivery/immunization regimen enhance the immune response against wild-type and drug-resistant HIV-1 reverse transcriptase, preserving its Th2-polarity.
Viruses and Oxidative Stress: Implications for Viral Pathogenesis.
病毒与氧化应激:对病毒发病机制的影响。
Oxid Med Cell Longev. 2019 Aug 19;2019:1409582. doi: 10.1155/2019/1409582. eCollection 2019.
密码子优化和改进的递送/免疫方案增强了针对野生型和耐药 HIV-1 逆转录酶的免疫反应,保持了其 Th2 偏向性。
Sci Rep. 2018 May 24;8(1):8078. doi: 10.1038/s41598-018-26281-z.
4
Fusion to Flaviviral Leader Peptide Targets HIV-1 Reverse Transcriptase for Secretion and Reduces Its Enzymatic Activity and Ability to Induce Oxidative Stress but Has No Major Effects on Its Immunogenic Performance in DNA-Immunized Mice.融合到黄病毒先导肽靶向 HIV-1 逆转录酶进行分泌,降低其酶活性和诱导氧化应激的能力,但对 DNA 免疫小鼠中的免疫原性性能没有重大影响。
J Immunol Res. 2017;2017:7407136. doi: 10.1155/2017/7407136. Epub 2017 Jun 22.
5
Electroporation as a vaccine delivery system and a natural adjuvant to intradermal administration of plasmid DNA in macaques.电穿孔作为一种疫苗传递系统,以及一种用于灵长类动物皮内给予质粒 DNA 的天然佐剂。
Sci Rep. 2017 Jun 23;7(1):4122. doi: 10.1038/s41598-017-04547-2.
6
Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C.直接作用抗病毒疗法可降低丙型肝炎肝硬化患者肝癌复发率。
Liver Int. 2017 Aug;37(8):1122-1127. doi: 10.1111/liv.13456. Epub 2017 May 25.
7
Immunotherapeutic approaches for hepatocellular carcinoma.肝细胞癌的免疫治疗方法。
Oncotarget. 2017 May 16;8(20):33897-33910. doi: 10.18632/oncotarget.15406.
8
Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma.美国退伍军人肝细胞癌患者队列中丙型肝炎抗病毒治疗的有效性。
J Hepatol. 2017 Jul;67(1):32-39. doi: 10.1016/j.jhep.2017.02.027. Epub 2017 Mar 4.
9
Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.肝细胞癌会降低使用直接作用抗病毒药物成功治疗丙型肝炎病毒的几率。
J Hepatol. 2017 Jun;66(6):1173-1181. doi: 10.1016/j.jhep.2017.01.020. Epub 2017 Feb 2.
10
Oxidative stress, a trigger of hepatitis C and B virus-induced liver carcinogenesis.氧化应激,丙型和乙型肝炎病毒诱导肝癌发生的一个触发因素。
Oncotarget. 2017 Jan 17;8(3):3895-3932. doi: 10.18632/oncotarget.13904.